Registration 333-299571
Underwriters: Jefferies, TD Cowen, Jefferies LLC, TD Securities LLC
Company research
Rezera Inc.
CIK 2141583Updated Nov 10, 2026
Name history
NODTHERA INC. · through Aug 21, 2026
Filing activity
Latest filing
4 filings on record · S-1/A, 8-A12B, S-1.
About the company
We are a clinical-stage biotechnology company developing a portfolio of internally invented, proprietary and wholly-owned oral inhibitors of NOD-like receptor protein 3, or NLRP3. NLRP3 is the upstream driver of sterile inflammation – inflammation that is caused by damage signals, such as cholesterol crystals or misfolded proteins, rather than by infection. NLRP3 activation triggers formation of the NLRP3 inflammasome, an intracellular protein complex involved in the body’s inflammatory response. NLRP3 activation directly stimulates the production of interleukin-1 beta, or IL-1β, and interleukin-18, or IL-18, which are potent pro-inflammatory cytokines. In turn, IL-1β stimulates production of another inflammatory molecule, interleukin-6, or IL-6. For this reason, this inflammatory cascade is referred to as the NLRP3/ IL-1β/IL-6/IL-18 pathway.
Recent filings
Offerings
Filing attachments
tmm-ex4d2.htm · S-1 · 2026-10-21
Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of July 15, 2026, by and among NodThera Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder”. RECITALS WHEREAS, certain of the Inv…
Read attachment ↗